The fund is rated 4 stars. The strongest areas were investment selection within each asset type and investment selection within each industry, while balance between returns and downside risk provided some support. Higher annual fee of 2.06% and above-average fund size of Rs 6,861.2 crore were minor drawbacks.
This fund has a good track record with Asset Selection/Timing, a good track record with Stock Selection/Timing. It is important to note, however, that this fund has a 6861.203 AUM and a 2.06 expense ratio. Considering all these factors, we have rated this fund as 4.0 star.
எங்கள் score நீண்டகால performance, risk மற்றும் consistency-ஐ மதிப்பிடுகிறது — past returns மட்டும் அல்ல.
5 Nov 2026 நிலவரப்படி
31 Oct 2026 நிலவரப்படி
30 Sep 2026 நிலவரப்படி
| Holding | Fund-இன் % | மதிப்பு | பங்குகள் |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 11.48% | ₹788.06 Cr | 43,38,091 |
| Dr. Reddy's Laboratories Ltd. | 9.73% | ₹667.57 Cr | 54,14,201 |
| Cipla Ltd. | 5.79% | ₹396.98 Cr | 29,49,351 |
| Biocon Ltd. | 5.33% | ₹365.74 Cr | 98,76,830 |
| Mankind Pharma Ltd. | 5.04% | ₹346.05 Cr | 13,82,093 |
| Alkem Laboratories Ltd. | 4.81% | ₹330.36 Cr | 6,39,791 |
| Medplus Health Services Ltd. | 4.31% | ₹295.65 Cr | 45,14,490 |
| Cohance Lifesciences Ltd. | 4.05% | ₹278.24 Cr | 62,66,692 |
| Divi's Laboratories Ltd. | 3.78% | ₹259.25 Cr | 2,79,019 |
| Syngene International Ltd. | 3.50% | ₹240.3 Cr | 65,78,033 |
Long term wealth creation. An Equity Scheme that predominantly invests in Equity and Equity related securities of companies in Healthcare Sector.
The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies.
Exit load of 1% if redeemed within 15 days.
மியூச்சுவல் ஃபண்டுகள் சந்தை ஆபத்துகளுக்கு உட்பட்டவை. அனைத்து scheme documents-ஐ கவனமாகப் படிக்கவும்.
